Actemra Injection
PDF Leaflet Revision Date: 26 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of severe rheumatoid arthritis and juvenile idiopathic arthritis.
Dosage (summary)
RA: 8 mg/kg IV every 4 weeks; pJIA: 10 mg/kg (<30 kg) or 8 mg/kg (u226530 kg) IV every 4 weeks; sJIA: 12 mg/kg (<30 kg) or 8 mg/kg (u226530 kg) IV every 2 weeks.
Onset of Action / Duration
Onset: 6-12 weeks for clinical improvement.
Special Populations
- Children
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- MTX
- CYP450 substrates
- TNF antagonists
Contraindications
- Hypersensitivity to tocilizumab
- Active severe infections
Common side effects
- Upper respiratory tract infections
- Headache
- Hypertension
- Increased ALT
Counselling Points
- Monitor for infections
- Avoid live vaccines
- Report any allergic reactions
- Regular lab monitoring for liver and blood counts
Serious warnings
- Serious infections
- Gastrointestinal perforation
- Hypersensitivity reactions
- Liver enzyme elevations
Important Disclaimer
The Actemra Injection professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
